San Diego, United States
Skye Bioscience Inc. is a pioneering company in the biotechnology and pharmaceutical industries, headquartered in the United States. Founded in 2011, the company is committed to "unlocking new therapeutic pathways for metabolic health," emphasizing novel treatments for metabolic conditions.
The core of Skye Bioscience's strategy involves the development of innovative molecules that target G-protein coupled receptors. Their flagship therapeutic candidate, nimacimab, is noted for its potential to inhibit CB1 peripherally. A significant milestone for the company is the planned Phase 2 clinical trial slated for Q3 2024 in obesity, comparing monotherapy and combination therapies involving a GLP-1R agonist, Wegovy®.
Noteworthy is Skye Bioscience's recent financial boost from a $50.25M Post-IPO Equity investment, finalized on 29 January 2024. This investment round was backed by prominent investors including 5AM Ventures, Ally Bridge Group, Altium Capital, Driehaus Capital Management, and Sphera Global Healthcare Fund, signaling strong confidence in the company's potential for clinical and commercial success.
